Simeprevir

Hepatitis C Virus NS3/4A Protease Inhibitor — ANTIINFECTIVES FOR SYSTEMIC USE

Key facts

Simeprevir is an ofm drug in the Hepatitis C Virus NS3/4A Protease Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2013. Its mechanism of action is classified as Bile Salt Export Pump Inhibitors, Breast Cancer Resistance Protein Inhibitors and Cytochrome P450 1A2 Inhibitors. DrugCentral lists 8 molecular targets, including Genome polyprotein, Nonstructural protein NS3-4A and Polyprotein. Recorded indications include Chronic hepatitis C.

• Approval status: ofm (first approved 2013 by the FDA).
• Drug class: Hepatitis C Virus NS3/4A Protease Inhibitor.
• Mechanism of action: Bile Salt Export Pump Inhibitors; Breast Cancer Resistance Protein Inhibitors; Cytochrome P450 1A2 Inhibitors.
• Molecular targets: Genome polyprotein, Nonstructural protein NS3-4A, Polyprotein and NS3 protease (8 listed in DrugCentral).
• Indications: Chronic hepatitis C.
• ATC code: J05AP05 (Antivirals for treatment of HCV infections).
• Molecular formula: C38H47N5O7S2; molecular weight 749.94 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Chronic hepatitis C

Mechanism & targets

• Mechanism of action (MoA): Bile Salt Export Pump Inhibitors; Breast Cancer Resistance Protein Inhibitors; Cytochrome P450 1A2 Inhibitors; Cytochrome P450 3A4 Inhibitors; HCV NS3/4A Protease Inhibitors; Multidrug Resistance-Associated Protein 2 Inhibitors; Organic Anion Transporting Polypeptide 1B1 Inhibitors; Organic Anion Transporting Polypeptide 1B3 Inhibitors; P-Glycoprotein Inhibitors; Sodium Taurocholate Co-transporting Polypeptide Inhibitors
• Established pharmacologic class: Hepatitis C Virus NS3/4A Protease Inhibitor

Molecular targets (8)

Target	Gene	Action	Activity
Genome polyprotein	—	inhibitor	Ki 9.44
Nonstructural protein NS3-4A	—	unknown	Ki 9.44
Polyprotein	—	inhibitor	Ki 9.44
NS3 protease	—	unknown	Ki 9.40
Hepatitis C virus serine protease, NS3/NS4A	NS3|NS4A	inhibitor	Ki 9.30
Genome polyprotein	NS3	unknown	Ki 9.30
Replicase polyprotein 1ab	REP	unknown	IC50 8.61
Cathepsin S	CTSS	unknown	IC50 6.10

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2014-05-14	EMA	—	—
2013-11-22	FDA	—	JANSSEN PRODS

ATC classification

ATC code	Therapeutic hierarchy
J05AP05	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Antivirals for treatment of HCV infections

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• FDA label: IFNL3 · Informative PGx
• HCSC label: IFNL3 · Informative PGx

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Anaemia	1364.3
Platelet count decreased	1311.5
Remission not achieved	965.2
Blood bilirubin increased	892.1
White blood cell count decreased	850.7
Hepatitis C	822.3
Hyperbilirubinaemia	593.4
Hepatocellular carcinoma	575.3
Photosensitivity reaction	435.8
Haemoglobin decreased	422.9
Neutrophil count decreased	402.6
Off label use	304.0

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Simeprevir is on its molecule page.

• Molecular formula: C₃₈H₄₇N₅O₇S₂
• Molecular weight: 749.94 g/mol
• CAS number: 923604-59-5
• InChIKey: JTZZSQYMACOLNN-VDWJNHBNSA-N
• PubChem CID: 24873435

COC1=C(C)C2=C(C=C1)C(O[C@@H]1C[C@@H]3[C@@H](C1)C(=O)N(C)CCCC\C=C/[C@@H]1C[C@]1(NC3=O)C(=O)NS(=O)(=O)C1CC1)=CC(=N2)C1=NC(=CS1)C(C)C

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Simeprevir used for?

DrugCentral lists the following indications for Simeprevir: Chronic hepatitis C.

How does Simeprevir work?

Simeprevir is classified as Bile Salt Export Pump Inhibitors, Breast Cancer Resistance Protein Inhibitors and Cytochrome P450 1A2 Inhibitors; its molecular targets in DrugCentral include Genome polyprotein (inhibitor), Nonstructural protein NS3-4A, Polyprotein (inhibitor) and NS3 protease.

When was Simeprevir first approved?

Simeprevir was first approved by the FDA in 2013.

What drug class does Simeprevir belong to?

Simeprevir is in the Hepatitis C Virus NS3/4A Protease Inhibitor class.

What is the chemical formula of Simeprevir?

Simeprevir has the molecular formula C38H47N5O7S2 and a molecular weight of 749.94 g/mol.

Sources

• DrugCentral drug card 4812 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL3137358 — compound record and bioactivity
• PubChem CID 24873435 — chemical identifiers
• DrugBank DB06290 — drug record
• FDA UNII 9WS5RD66HZ — substance identity
• DailyMed: FDA labels for Simeprevir — current prescribing information (label search)
• UniProt P25774 (CTSS) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.